Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

This is an open-label 2-arm trial. Eligible subjects will be screened and enrolled
sequentially into 1 of 2 Arms:

Arm I: N=6 to 12 subjects, Safety Phase

- Cohort 1 SPL-108 x 1 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28
day cycles

- Cohort 2 SPL-108 BID + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles

For Arm I, at least 1 week will elapse between Dose 1 for each subject.

In Cohort 1, 3 subjects will be enrolled: if 1 dose-limiting toxicity (DLT) occurs, 3
subjects will be added at this dose level; if 0/3 or 1/6 DLTs occur, Cohort 2 will initiate
enrolling subjects; if 2 or more DLTs occur at this dose level, subjects will not be enrolled
in Cohort 2 and the trial will be terminated.

In Cohort 2, 3 subjects will be enrolled: if 1 DLT occurs, 3 subjects will be added at this
dose level; if 0/3 or 1/6 DLTs occur, Arm II will initiate enrolling subjects at the SPL-108
BID dose; if 2 or more DLTs occur, Arm II will initiate enrolling subjects at the SPL-108
dose one time each day.

Arm II: N=up to 12, Exploratory Expansion Phase

• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1,
8, and 15 in 28 day cycles.

A Safety Committee will meet at the end of each Arm I Cohort as well as periodically to
review safety data and make recommendations for trial progression. The primary efficacy
outcome, Response Evaluation Criteria in Solid Tumors Committee (RECIST 1.1) criteria, will
be assessed on Day 15 of Cycles 2, 4, and 6.

Inclusion Criteria:

1. Females ≥18 years of age

2. Platinum-resistant recurrent or metastatic epithelial ovarian carcinoma

3. Positivity on CD44 assay as defined by strong (+++) or moderate (++) staining in 20%
or more of the tumor tissue/stroma as obtained by biopsy or paracentesis

4. Status post first-line therapy with definitive surgery (which provided tissue for
pathologic diagnosis) and chemotherapy

5. Original diagnosis has been confirmed through a histopathologic review of the primary
tumor slides by an expert pathologist at the Principal Investigator's institution

6. Disease has progressed or recurred during or less than 6 months after platinum-based
chemotherapy at some point during the subject's course.

7. No more than 3 prior regimens of cytotoxic chemotherapy unless approved by the sponsor
(Note: all platinum-containing regimens are not to be counted separately but are
considered to be a single regimen for the purposes of this criterion)

8. Measurable disease by RECIST 1.1 criteria

9. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2

10. Women with childbearing potential and partners must both use effective contraception
during the study and for 3 months after the last dose

11. Life expectancy of at least 6 months

12. Able to understand and comply with the study procedures, understand the risks involved
in the study, and provide written informed consent before the first study-specific
procedure

Exclusion Criteria:

1. Treatment with cytotoxic chemotherapy for malignancies other than ovarian cancer
within the past 5 years

2. Fewer than 28 days before Cycle 1 Day 1 since any prior chemotherapy (less than 42
days in the case of mitomycin or a nitrosourea)

3. Fewer than 28 days before Cycle 1 Day 1 since administration of hormonal or biological
anti-neoplastic agents

4. Concomitant use of other cytotoxic or cytostatic drugs other than PTX

5. Abnormal clinical laboratory values within 14 days prior to initiation of dosing, as
indicated by:

- Hemoglobin level <9.0 gm/L

- Platelet count <100,000/mm3

- Granulocyte count <1500/mm3

- Serum creatinine level ≥2.5 mg/dL (221 μmol/L)

- Liver aminotransferase levels greater than 3 times the laboratory's upper limit
of normal (greater than 5 times the laboratory's upper limit of normal if the
liver is known to be involved with tumor)

6. Contraindication to the use of PTX

7. Pregnancy or breast-feeding at time of Screening and throughout the study.

8. Active, uncontrolled infection

9. Participation in another investigational drug trial concurrently or within 30 days of
Cycle 1 Day 1, or a vaccine trial within 90 days of Cycle 1 Day 1

10. Significant acute or chronic medical or psychiatric illness that, in the judgment of
the Investigator, could compromise subject safety, limit the subject's ability to
complete the trial, and/or compromise the objectives of the trial